Quarterly report [Sections 13 or 15(d)]

STOCKHOLDERS’ EQUITY

v3.26.3
STOCKHOLDERS’ EQUITY
9 Months Ended
Sep. 30, 2026
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 8. STOCKHOLDERS’ EQUITY

 

Shares of the Company’s Class A common stock have both voting and economic rights, including the right to receive dividends or distributions, if declared, and proceeds upon dissolution, winding up or liquidation. Each share of Class A common stock entitles the holder to one vote on all matters submitted to stockholders. All Class B common stock was converted into Class A common stock in December 2022; accordingly, no shares of Class B common stock remain outstanding.

 

Reverse Stock Splits

 

Effective June 26, 2025, the Company completed a one-for-750 reverse stock split of its issued and outstanding shares of Class A common stock. As a result, every 750 shares of Class A common stock issued and outstanding were converted into one share of Class A common stock. In lieu of issuing fractional shares, the Company rounded fractional shares up to the next whole share.

 

On April 2, 2026, the Company filed a Certificate of Amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a one-for-eight reverse stock split of its issued and outstanding shares of Class A common stock, effective April 6, 2026. As a result, every eight shares of Class A common stock issued and outstanding were converted into one share of Class A common stock. No fractional shares were issued in connection with the reverse stock split. In lieu of fractional shares, stockholders otherwise entitled to receive a fractional share received a cash payment equal to such fraction multiplied by the closing sales price of the Class A common stock as reported on the Nasdaq Capital Market on the trading day immediately preceding the effective date of the reverse stock split.

 

The reverse stock splits did not change the par value of the Class A common stock or the authorized number of shares of Class A common stock. All share and per-share amounts presented in these condensed consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to the reverse stock splits.

 

 

Warrants

 

The Company has issued warrants in connection with prior equity financing transactions, restructuring and exchange transactions, and strategic advisory arrangements. The Company’s warrants are classified as equity instruments when they are indexed to the Company’s own stock and meet the criteria for equity classification.

 

During the nine months ended September 30, 2026, the Company did not issue any warrants. During the three months ended September 30, 2026, warrants to purchase 66,700 shares of Class A common stock were exercised. During the nine months ended September 30, 2026, warrants to purchase an aggregate of 157,662 shares of Class A common stock were exercised. Because certain pre-funded warrants were substantially funded at issuance and have a nominal exercise price, exercises of such warrants did not result in material cash proceeds and were reflected as reclassifications within stockholders’ equity.

 

Warrant activity for the nine months ended September 30, 2026 was as follows:

 

   

Number of

Warrants

   

Weighted Average

Exercise Price

 
             
Balance, December 31, 2025     3,882,755     $ 0.08  
Issued     —       —  
Expired or rescinded     (283 )     —  
Exercised     (157,662 )     0.08  
Balance, September 30, 2026     3,724,810     $ 0.08  

 

As of September 30, 2026, outstanding warrants have a weighted average remaining life of 4.91 years.

 

For the three and nine months ended September 30, 2026, the Company recognized approximately $0.2 million and $0.7 million, respectively, of non-cash stock-based compensation expense related to strategic advisory warrants issued to non-employee service providers. These expenses are presented separately as stock-based compensation – strategic advisory warrants in the condensed consolidated statements of operations and comprehensive income (loss). As of September 30, 2026, there was no unrecognized compensation expense related to strategic advisory warrants.

 

No warrants were issued during the nine months ended September 30, 2026. Accordingly, no grant-date valuation assumptions are presented for the period.

 

Net Income (Loss) Per Share

 

Basic net income (loss) per share of Class A common stock is computed by dividing net income (loss) attributable to Greenlane Holdings, Inc. by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted net income (loss) per share of Class A common stock is computed by dividing net income (loss) attributable to Greenlane Holdings, Inc. by the weighted-average number of shares of Class A common stock outstanding, adjusted to give effect to potentially dilutive securities.

 

Pre-funded warrants with nominal exercise prices are included in the weighted-average number of shares outstanding for purposes of calculating basic net income (loss) per share beginning on their respective issuance dates because the exercise price is non-substantive and exercise is considered virtually assured.

 

 

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per share of Class A common stock is as follows:

 

(in thousands, except share and per share data)   2026     2025     2026     2025  
    Three months ended
September 30,
    Nine months ended
September 30,
 
(in thousands, except share and per share data)   2026     2025     2026     2025  
Numerator:                                
Net income (loss)   $ 4,433     $ (8,933 )   $ (38,611 )   $ (16,015 )
Less: Net income (loss) attributable to non-controlling interests     —       —       149       —  
Net income (loss) attributable to Class A common stockholders   $ 4,433     $ (8,933 )   $ (38,760 )   $ (16,015 )
Denominator:                                
Weighted average shares of Class A common stock outstanding - basic     3,855,926       173,319       3,838,647       100,686  
Net income (loss) per share of Class A common stock - basic   $ 1.15     $ (51.54 )   $ (10.10 )   $ (159.06 )
Dilutive effect of warrants (treasury stock method)     557,939       —       —       —  
Weighted average shares of Class A common stock outstanding - diluted     4,413,865       173,319       3,838,647       100,686  
Net income (loss) per share of Class A common stock - diluted   $ 1.00     $ (51.54 )   $ (10.10 )   $ (159.06 )

 

For the nine months ended September 30, 2026 and the three and nine months ended September 30, 2025, stock options and warrants were excluded from diluted net loss per share because their effect would have been anti-dilutive due to the net loss. For the three months ended September 30, 2026, diluted net income per share reflects the dilutive effect of strategic advisory warrants under the treasury stock method; stock options and certain warrants were excluded because their exercise prices exceeded the average market price of the Class A common stock.

 

Revision of Previously Reported Net Loss per Share. In connection with the preparation of these condensed consolidated financial statements, the Company identified an error in the weighted-average number of shares of Class A common stock used to compute basic and diluted net loss per share for the year ended December 31, 2025, the three months ended March 31, 2026, and the three and six months ended June 30, 2026. The weighted-average share count excluded shares of Class A common stock issued in the Company’s October 2025 private placement and included warrants other than pre-funded warrants. The error had no effect on the Company’s net loss, balance sheets, statements of stockholders’ equity or statements of cash flows. The Company evaluated the error under ASC 250 and SEC Staff Accounting Bulletin No. 99 and concluded it was not material to any previously issued financial statements. As corrected, basic and diluted net loss per share was $(105.53) for the year ended December 31, 2025 (previously $(91.39)), $(4.80) for the three months ended March 31, 2026 (previously $(4.49)), $(6.48) for the three months ended June 30, 2026 (previously $(6.06)) and $(11.28) for the six months ended June 30, 2026 (previously $(10.60)). Amounts for these periods will be revised when presented in future filings.

 

The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive (in common stock equivalent shares):

 

    2026     2025     2026     2025  
    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
Stock options to purchase common stock     235,000       1       235,000       1  
Warrants to purchase common stock*     3,436       3,944       630,122       3,944  

 

  * Pre-funded warrants with nominal exercise prices are included in basic weighted-average shares and excluded from this table.